The immunotoxin approach is based on the use of tumortargeting ligands or antibodies that are linked to the catalytic (toxic) moieties of bacterial or plant protein toxins. In this review, we first discuss the current state of clinical development of immunotoxin approaches describing the results obtained with the two toxins most frequently used: diphtheria and Pseudomonas toxin-derived proteins. In the second part of the review, a novel concept will be presented in which the roles are inverted: nontoxic receptor-binding toxin moieties are used for the targeting of therapeutic and diagnostic compounds to cancer or immune cells. The cell biological basis of these novel types of toxin-based therapeutics will be discussed, and we will summarize ongoing preclinical and clinical testing.
Introduction
Management of unresectable or metastatic tumors is based on the cytotoxic effect of radiotherapy and/or chemotherapy. Numerous toxin-based therapies have been developed in this field for their potent cell-killing activity. However, because of the nonspecific effects of toxins on normal and tumor cells, targeting of cancer cells generally remains a prerequisite for such therapeutic applications. Targeting of toxins to cancer cells has used a variety of modalities, namely (1) a direct interaction between the toxin and its natural receptor expressed on tumor cells; (2) vectorization of the toxin by a natural ligand or a monoclonal antibody that specifically recognizes cancer cells that express their natural receptors; and (3) gene therapy allowing cellular penetration of a viral vector expressing the toxin. In addition to these direct cancer cell cytotoxic approaches, a few publications have reported anticancer immune activation via T-lymphocytes, natural killer cells, or dendritic cells with tumor-directed targeting by toxin compounds.
The most developed class of targeted cytotoxic treatments is constituted by immunotoxins. The immunotoxin approach is based on the use of tumor targeting ligands or antibodies that are linked to the catalytic moieties of bacterial or plant protein toxins. The targeted toxin induces apoptosis by reaching the cytosol and inactivating vital cell processes or by modifying the tumor cell surface membrane. In this review, we will first discuss the current state of clinical development of immunotoxin approaches, focusing on clinical trials using diphtheria and Pseudomonas exotoxin (PE)-derived proteins, and we will indicate their limitations. In the second part of the review, a novel concept will be presented in which the roles are inverted: nontoxic receptor-binding toxin moieties are used for the targeting of diagnostic and therapeutic compounds to cancer cells or immune cells. This approach exploits many of the characteristics that receptor-binding toxin moieties have acquired throughout evolution, such as stability, capacity to cross tissue barriers, and their unique intracellular distribution pathways. The cell biological basis of these novel types of toxin-based therapeutics will be discussed, with a presentation of ongoing preclinical and clinical testing.
Recombinant immunotoxins
To be used in clinical practice for cancer therapy, toxins must meet a number of stringent criteria: (1) the toxin must possess a very high inherent toxicity, in the low nanomolar range, 1 because expression of the targeted receptors is usually less than 10 5 molecules per cell. For example, one molecule of diphtheria toxin (DT), which is one of the two toxins most often used for cancer therapeutics, is sufficient to kill a cell; 2 (2) the toxin compound, which includes the ligand of the target receptor, the toxin and, in most cases, a linker, should preserve the main characteristics of the toxin; (3) delivery of the toxin compound requires internalization of the toxin after binding to the surface of cancer cells, as internalization leads to the apoptotic effect. Indeed, unlike radioisotope immunoconjugates, most toxins only kill cells once they are inside the cytosol; 3 (4) the toxin must be able to survive proteolytic processing and the acidic environment of lysosomes. Intracellular trafficking of the toxin therefore appears to be a checkpoint for the desired cytotoxic effect; 4 and (5) in most, but not all, situations, the toxin must be delivered from its targeting compound to be in an active form. 1 There are three classes of immunotoxins: class I toxins, mainly used for hematologic malignancies, are intracellular enzymes blocking cytosolic protein synthesis either by modifying elongation factor 2 (DT and PE) or ribosomal RNA (ricin, gelonin, saporin, etc), or by degrading total RNA (angiogenin, ribonuclease); 4 class II toxins such as the Fab fragment of the antiCD25 monoclonal antibody fused to phospholipase C 5 bind to the cell surface and trigger intracellular signaling pathways; class III toxins are pore-forming peptides leading to leaks in the plasma membrane; these include mellitin, 6 the plant Pyrularia thionin peptide, 7 and the cobra venom cationic 63 amino-acid membrane lytic peptide toxin. 8 Various toxins have been used, but the two bacterial toxins most frequently exploited for cancer treatments are DT and PE. Numerous targets have been used to accumulate immunotoxins on cancer cells, namely cluster designation differentiation antigens, cytokine receptors (interleukin-2 receptor, IL-3R, IL-4R, IL-6R, IL-7R, IL-9R, IL-13R, IL-15R, granulocyte-macrophage colony-stimulating factor receptor (GM-CSFR), granulocyte colony-stimulating factor receptor (G-CSFR), transferrin receptor, and urokinase receptor), and a heterogeneous group of cell membrane receptors (human leukocyte antigen-DR, immunoglobulin idiotype, IgMFc, etc). 4 Clinical trials performed with DT-and PE-derived proteins will be presented.
DT-derived proteins
A very large number of DT fusion proteins have been developed and tested in preclinical models: (1) DT/GM-CSF fusion protein (DT 388 GMCSF) for acute myeloid leukemia; (2) DT/IL2 fusion protein (Denileukin Diftitox) for lymphoid malignancies; (3) DT/IL3 for acute myeloid leukemia and glioblastoma multiforme; (4) DT/ IL4 for acute myeloid leukemia; (5) DT/epidermal growth factor (EGF) for acute myeloid leukemia, glioblastoma multiforme, and pancreatic cancers; (6) DT/vascular endothelial growth factor with an antiangiogenic effect for the treatment of breast and pancreatic carcinomas; (7) DT/alpha-fetoprotein for hepatoblastoma; (8) DT/human chorionic gonadotropin for ovarian cancers; (9) DT/gastrin-releasing peptide for small cell lung cancer cells; and (10) 11 and 24% in B-cell NHL, including 7% of complete responses. 12 A phase I trial with DT/GMCSF fusion protein (DT 388 GMCSF) on 31 patients with refractory or relapsed acute myeloid leukemia 13 also revealed dose-related toxicity such as liver injury observed in two out of eight cases receiving 4.5-5 mg/kg/day. Other toxicities were mild, namely fever, chills, hypoxemia, and transient postinfusion hypotension. After 15-60 days of treatment, 21 of 25 patients that could be evaluated had a significant increase of antibody titers. Only three clinical responses were obtained (10%) with only one complete response.
PE-derived proteins
As for DT, various ligands have been fused to PE, mainly IL-4, IL-13, and EGF, and tested in various tumor cell lines or xenografted tumors expressing the corresponding receptors. In contrast, various heterogeneous clinical trials have been performed with PE-derived protein, as shown in Table 1 . In malignant gliomas, targeted toxin was directly delivered to tumors using stereotactic catheters. [14] [15] [16] In these four studies, neurological toxicity was observed with increases of intracranial pressure most probably related to infusion volume, recurrent tumor, or stereotactic catheter placement; a few cases of fatigue and emesis were also described. The most frequent toxicity observed in clinical trials performed on benign brain tumors was vascular leak syndrome, 17 nausea/vomiting, 17, 18 diarrhea, 17 pain and inflammation at injection sites, 19 and elevation of transaminase levels. 18 The response rates are presented in Table 1 , showing extensive tumor necrosis defined on MRI scans in Intracellular trafficking for targeted therapy L Johannes and D Decaudin malignant glioma trials, and a 23% response rate after anti-CD25-PE38 in patients with CD25-positive hematologic malignancies. 18 Immunogenicity of the recombinant immunotoxin anti-CD25-PE38 (LMB-2) was well evaluated. 18 Neutralizing antibodies were defined by at least 50% neutralization of cytotoxicity when serum was incubated with LMB-2. By this criterion, 22 of 35 patients (63%) had neutralizing antibodies after one injection cycle, nine of 12 patients (75%) after two cycles, and four of five patients (80%) after three cycles. In all patients, neutralizing anti-LMB-2 antibodies were directed against the toxin portion of LMB-2, and in eight of 10 patients with strongly neutralizing antibodies had also developed human anti-mouse antibodies. The authors concluded that LMB-2 was not very immunogenic (at least for the production of neutralizing antibodies) in patients immunosuppressed because of their tumor and previous therapy, such as patients with heavily pretreated malignant NHL.
Lessons from immunotoxins
Recombinant immunotoxins used in cancer therapy should address a number of general rules whose importance has become apparent in clinical studies as those summarized above: tumor specificity and favorable biodistribution between normal and tumor tissues, acceptable levels of nontumoral toxicity with maximal cancer cell cytotoxicity, lack of significant immunogenicity allowing repeated administrations, and favorable pharmacological profile in term of extra-and intracellular compartment half-life. From this point of view, the use of immunotoxins in clinical trials has identified various limitations to their development, namely: (1) specific toxicities of immunotoxins have been observed. The raised intracranial pressure observed after intratumoral delivery of toxin-derived compounds in glioma patients is not due to the toxin. [14] [15] [16] In contrast, vascular leak syndrome secondary to vascular injury may be due to selective receptors for peptide toxins on endothelial cells. 20, 21 A modification of the endothelial binding residues on toxins may reduce this toxicity. Reaction of immunotoxins with macrophages and lymphocytes leads to the release of cytokines such as IL-6 and TNFa with constitutional symptoms. 13, [22] [23] [24] Corticosteroids appear to reduce or eliminate this side effect. 21 (2) Pharmacologic problems have been observed. Small immunotoxins of less than 50 kDa, such as DT-derived proteins, are rapidly cleared by the kidney glomeruli leading to a short half-life of 1-5 h, 9, 13, 23 reduced area under the curve, and renal tubular injury. 13 In contrast, penetration into extravascular sites of disease is better with small toxin-derived compounds, reducing endothelial toxicity and increasing tumor targeting efficacy. 4 However, there are no reports to date regarding the saturation of extravascular tumor deposits in clinical trials with recombinant immunotoxins. In others words, the proximal tumor tissue is exposed to high therapeutic concentrations, whereas the middle portion is to therapeutic concentrations, and the distal portion of the tumor is to subtherapeutic concentrations. 25 (3) Efficacy of immunotoxins is influenced by their immunogenicity, as patients with antibodies directed against toxins rapidly clear immunotoxins from the bloodstream and have a markedly reduced area under the curve. For DTderived compounds, most people are immunized with DT leading to a significant pretreatment blood antibody titer in many patients and the development of an amnestic immune response after DT conjugate therapies. Decreased immunogenicity has been observed with toxins that are foreign antigens to which patients have not been previously exposed, but antitoxin antibodies appear after a lag of 3-4 weeks. 26 (4) Cytotoxicity of the immunotoxin depends on its intratumor cell internalization and intracellular trafficking. In particular, DT can escape from early endosomes to the cytosol, while PE and ricin toxin only reach the cytosol after passage through the Golgi apparatus and endoplasmic reticulum (see below), and this clearance by intracellular components influences the cytotoxicity of the toxins. 4 No data concerning saturation of extravascular tumor sites have been obtained on toxin-derived compound internalization and intracellular trafficking in reported clinical trials using immunotoxins. All these comments emphasize the difficulties involved in the development of a toxinderived therapeutic approach for the treatment of cancer.
Intracellular toxin trafficking pathways and mechanisms
The study of immunotoxins has paid much attention to the catalytic (toxic) moieties of protein toxins and the associated membrane translocation domains. However, the receptor-binding parts of these toxins are more than simple devices to hook the toxins onto cells. In some cases, they follow unique intracellular trafficking pathways and have been instrumental in the discovery of these pathways. The most prominent examples are clathrin-independent endocytosis and retrograde transport ( Figure 1) . In this paragraph, we will summarize the current knowledge on unusual toxin trafficking pathways. The following paragraph illustrates how this knowledge may guide the development of novel types of targeting strategies in which receptor-binding toxin moieties are combined with diagnostic or therapeutic compounds.
Toxins enter cells by various endocytotic mechanisms
The most extensively studied endocytosis mechanism is still the clathrin-dependent pathway. Clathrin is an ubiquitous cytosolic protein that can be recruited to membranes, directly or via so-called adaptor proteins. 27 Clathrin has the remarkable capacity of forming different types of lattices, flat or basket-like, and it is commonly believed that the latter favour membrane deformation during the budding process of vesicles, at the plasma membrane or on internal membranes. Some protein toxins, such as DT 28 and anthrax toxin, 29 exclusively use the clathrin pathway (Figure 1 ). This is achieved by binding to specific transmembrane domain protein receptors -heparin-binding EGF-like growth factor precursor 30 and anthrax toxin receptor, 31 respectively. In other cases, it has clearly been established that entry can also occur in a clathrin-independent manner.
In fact, protein toxins were the first cargoes that were used to identify clathrin-independent endocytosis mechanisms. Cholera toxin, tetanus toxin, and ricin were Intracellular trafficking for targeted therapy L Johannes and D Decaudin found in smooth noncoated plasma membrane invaginations, and interfering with clathrin-dependent endocytosis using potassium depletion or cytosol acidification did not prevent their entry into cells. 28, [32] [33] [34] These initial observations, based on the use of relatively nonspecific inhibitors, were subsequently confirmed by using tools that allow a direct inhibition of clathrin function. Thus, when clathrin expression was downmodulated, Shiga toxin still entered cells efficiently. 35, 36 For cholera toxin, similar conclusions were reached using dominant-negative mutants of clathrin interacting proteins 37 and morphological approaches. 38 While it is now well established that these toxins and others can use clathrin-independent mechanisms to enter cells, it must be kept in mind that very often several pathways, clathrin-dependent or not, can serve as entry portals (see eg Sandvig et al 39 and Saint-Pol et al 35 for Shiga toxin), and endocytic plasticity, that is, the capacity to use several endocytic pathways, is a common trait to many of the known protein toxins (Figure 1) .
The mechanisms of clathrin-independent endocytosis remain elusive. The best correlation has been established with the association of toxins with membrane microdomains of the raft-type, enriched in glycosphingolipids, cholesterol, and long-chain phospholipids. Cholera toxin binds to a glycosphingolipid, ganglioside GM1, and as such has become an archetypical raft marker. 40 The same is true for Shiga toxin, which binds to Gb3. 41, 42 Just how raft-type microdomains are involved in endocytosis and whether cellular proteins are also involved have yet to be established. It should also be pointed out that the dichotomy between clathrin-dependent endocytosis and endocytosis involving raft-type microdomains may not be as stringent as initially thought (see Johannes and Lamaze 43 for a review on cellular proteins). As for other toxins, cholera toxin is raft-associated in neurons, but enters these cells via the clathrin pathway, 44 and anthrax toxin behaves in a similar way in several cell lines. 29 The best-studied rafts are caveolae (for a review, see Parton 45 and van Deurs et al 46 ). It is often assumed that these are internalization structures that bud off from the plasma membrane, similar to clathrin-coated vesicles. In favour of this hypothesis, it has been described that the GTPase dynamin was involved in caveolar endocytosis, 47 ,48 much as it has been implicated in the budding of clathrin-coated pits. Other work indicated, however, that the role of caveolae in endocytosis may be more complex than initially assumed. In one study, cholera toxin used the clathrin pathway in cells that express low levels of caveolin-1, but shifted to clathrin-independent endocytosis when caveolin-1 was high. 49 Other reports have shown that caveolae are very poorly dynamic; 50 that cells lacking caveolae can still internalize cholera toxin; [51] [52] [53] and that caveolin-1 overexpression inhibits rather than ). Black arrows indicate the classical transport pathways. Diphtheria toxin and anthrax toxin enter cells by clathrin-dependent endocytosis. Shiga and cholera toxins can enter cells at least in part through clathrinindependent endocytosis, in addition to clathrin-dependent endocytosis (red arrows). The blue circle represents the interface between early and recycling endosomes and the trans-Golgi network. Shiga toxin and some other toxins such as cholera toxin, ricin, and Pseudomonas exotoxin, reach this interface and are then transported to the Golgi apparatus via the retrograde route (red arrow). Notably the use of Shiga toxin has allowed to identify the first molecular players at this interface. The retrograde pathway is distinct from the well known retrieval pathway used by the mannose 6-phosphate receptor (MPR), even tough recent evidence suggests that the MPR may also use the early and recycling endosomes-TGN interface.
35 Shiga and cholera toxins are then transported from the Golgi apparatus to the endoplasmic reticulum (red arrow), bypassing the classical KDEL-receptor/COPI recycling pathway (blue arrow). Sulfation and glycosylation on corresponding Shiga toxin B-subunit variants are used to detect and quantify the retrograde transport of the protein to the trans-Golgi network and to the endoplasmic reticulum, respectively. 64 From the lumen of the endoplasmic reticulum, catalytic toxin subunits are then retrotranslocated to the cytosol.
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stimulates endocytosis. 54, 55 It appears that caveolae have to be stimulated to become dynamic, as has been nicely shown for the cellular entry of simian virus. 40, 56 The complexity of clathrin-independent endocytosis is further illustrated by a very recent study in which cholera toxin was again used as the tool. 38 In this study, it was observed that the toxin could enter cells in a clathrin-, caveolin-, and dynamin-independent manner. This new pathway had previously been observed for GPI-anchored proteins. 57 It appears to operate via uncoated tubular or ring-shaped structures. Its importance for intoxication of cells remains to be formally demonstrated.
Intracellular toxin distribution pathways
Once they have entered cells, protein toxins are found in early and recycling endosomes (Figure 1) . For some toxins, such as diphtheria and anthrax toxin, acidification allows translocation of the catalytic A-subunits to the cytosol. Other toxins, such as Shiga toxin, cholera toxin, ricin, and PE, do not have this capacity. They follow a recently discovered pathway -the retrograde route -from early and recycling endosomes to the endoplasmic reticulum, via the Golgi apparatus, [58] [59] [60] from where their catalytic A-subunits are translocated to the cytosol, using the cellular retrotranslocation machinery ( (Figure 1 ). The critical step of the retrograde pathway is escape from endosomes. Quantitative tools based on Shiga toxin B-subunit 64 have been instrumental for the molecular description of retrograde sorting at the interface between early and recycling endosomes and the trans-Golgi network (TGN), a tubular membrane network at the trans-side of Golgi cisternae. It was shown that this transport step depends on the following proteins ( Figure  1 ): SNARE fusion proteins that are found on early and recycling endosomes or the TGN, 65, 66 clathrin, 35 ,36 the clathrin adaptor epsinR, 35 the GTPases dynamin 36 and Rab6a', 65 GPP130 protein, 67 and the GRIP-domain protein Golgin-97. 68 In addition to this protein machinery, lipid microcompartmentalization has also been hypothesized as a sorting factor on early/recycling endosomes. 42, 69 Nonassociation with lipid microdomains and the resulting failure to enter the retrograde pathway may indeed explain why some cells, such as monocytes, 70 macrophages, 71 and bovine intestinal epithelial cells, 72 are resistant to Shiga toxin, despite expression of Gb3.
Apart from Shiga toxin, ricin has also been used to demonstrate the implication of dynamin, 73 cholesterol, 74 calcium, 75 and protein kinase A 76 in retrograde sorting. Some recent studies have also indicated the possibility that endosomes may be present in the early endocytic pathway that are different from the 'conventional' transferrin receptor-positive early and recycling endosomes. These endosomes have been called 'caveosomes', and they were found to be involved in the cellular entry of simian virus 40. 77 They also contain cholera toxin. However, their role in cholera toxin trafficking still remains uncertain.
From the TGN/Golgi apparatus, the protein toxins that use the retrograde route are delivered to the endoplasmic reticulum. The 'classical' recycling pathway at the interface between the Golgi apparatus and the endoplasmic reticulum uses the retrieval receptors and the COPI membrane coat. This is the case for resident proteins of the endoplasmic reticulum that are recycled from Golgi cisternae after escaping from their steadystate localization in the endoplasmic reticulum (for a review, see, Pelham 78 ). The retrieval signals are basic amino acids found at the C-or N-termini of type I or type II trans-membrane proteins, respectively, or the KDEL tetrapeptide at the C-terminus of luminal proteins. When retrieval signal-tagged resident endoplasmic reticulum proteins encounter sorting receptors in the intermediate compartment or in Golgi cisternae, their retrograde transport to the endoplasmic reticulum is induced. The retrograde sorting machinery at the Golgi-endoplasmic reticulum interface includes components of the COPI coat, which interact directly with retrieval signals, and mutation of which has been correlated with retrieval phenotypes (for a review, see, Cosson and Letourneur 79 ) . Surprisingly, many protein toxins can reach the endoplasmic reticulum in a COPI/KDEL-receptor independent manner. This question was directly addressed for the first time by using the B-subunit of Shiga toxin. The B-subunit does not carry a KDEL signal, and adding the signal to the protein did not increase its retrograde transport efficiency, as determined by a quantitative assay. 80 However, it was not determined how cell intoxication was influenced by the addition of KDEL. This was recently performed using cholera toxin. 81 The catalytic A-subunit of cholera toxin carries a KDEL signal, but not the receptor binding B-subunit. As described for Shiga toxin B-subunit, 80 adding the KDEL signal to the B-subunit directly, or via the A-subunit, did not enhance retrograde transport. Intoxication, however, was slightly increased by the KDEL signal. These glycosphingolipid-binding toxins therefore appear to reach the endoplasmic reticulum via an as yet ill-defined mechanism bypassing the classical COPI/KDEL-receptor recycling loop. However, once they reach the endoplasmic reticulum, they become substrates for the KDELreceptor system, which increases their steady-state concentration in this compartment, and therefore the probability for retrotranslocation.
This hypothesis explains earlier findings concerning the relatively small effect on cell intoxication of KDEL signals, when deleted from various toxins (see Johannes and Goud 60 for a review). It also explains why the various methods used to interfere with COPI/KDELreceptor machinery had no effects on toxin retrograde transport and/or cell intoxication by Shiga toxin, 82 cholera toxin, 83 and ricin. 84 
Therapeutic applications of toxin trafficking
The trafficking characteristics of some of the abovementioned protein toxins have inspired the development of biomedical research aimed at targeting diagnostic or therapeutic compounds not only to specific cells but even to specific compartments within these cells. A prominent example is the use of protein toxins for the targeting of antigens to the MHC class I pathway of dendritic cells. These cells are currently considered to be the most potent inducers of cytotoxic T-CD8+ lymphocyte responses. They have the remarkable capacity to present not only antigens that are produced by these Intracellular trafficking for targeted therapy L Johannes and D Decaudin cells but also exogenous antigens. 85, 86 This process, termed cross-presentation, is remarkable as it involves the transfer of antigens from the outside where they are released, for example by necrotic cancer cells, to the cytosol where class I presentation starts with the clipping of antigenic proteins by proteasomes. From this point of view, cross-presentation has similar requirements to protein toxins: an exogenous protein -antigen or catalytic A-subunit -needs to cross membranes to reach cytosolic machinery -proteasomes or molecular targets such as ribosomal RNA. Various protein toxins have been used for the delivery of antigens into the class I pathway of dendritic cells (see Smith et al 87 for a review). More recently, two of them have been more particularly followed up because of their capacity to specifically target dendritic cells: the nontoxic B-subunit of Shiga toxin, and a detoxified variant of Bordetella pertussis adenylate cyclase toxin (CyaA).
Shiga toxin B-subunit binds to the cellular toxin receptor, the glycosphingolipid globotriaosyl ceramide (Gb3 or CD77). It was observed that Gb3 is specifically expressed on human and mouse dendritic cells and that the B-subunit is able to cross membranes into the cytosol in these cells. 42, 88 By incubating dendritic cells with Bsubunit-coupled antigenic peptides or full-size proteins, it was shown that antigenic peptides were presented by both MHC class I and II molecules. 89, 90 Vaccination of mice with B-subunit coupled to various antigenic peptides or full-size antigenic proteins induced a T-CD8+ response without the use of adjuvant. 88, 90 The B-subunit-induced immune response was TH1 polarized. 90 Since TH1 responses play an important role in protection against intracellular pathogens and tumors, the induction of TH1 polarization is highly desirable for vaccines designed to target these diseases. Recent data show that prophylactic or therapeutic vaccination of mice with B-subunit-vectorized antigens leads to tumor protection (LJ and Eric Tartour, unpublished).
Similar characteristics have been observed for CyaA, [91] [92] [93] [94] [95] which binds to dendritic cells via alpha(M)-beta(2) integrin. 96 A second example for the use of receptor targeting toxin subunits for biomedical applications is found in the domain of cancer cell targeting. The Shiga toxin receptor, Gb3, has been reported to be overexpressed by a certain number of human tumors, such as Burkitt lymphomas, 97 acute nonlymphocytic leukemia, 98 ovarian 99 and breast 100 carcinomas, testicular seminomas, 101 and various cancer cell lines. Shiga toxin B-subunit could therefore possibly be used to target diagnostic or therapeutic compounds to these tumors. This approach has been pioneered at the preclinical stage using Shiga holotoxin itself. It was shown that intratumoral injection of Shiga toxin inhibits tumor growth. [102] [103] [104] Another potential application of Shiga toxin is the control of tumor neo-angiogenesis 105 and purging of residual tumor burden from a human B-cell lymphoma xenograft, while sparing normal hematopoietic precursor cells. 106 As a further refinement of the cancer cell targeting approach, it might be suggested to replace the catalytic A-subunit of Shiga toxin by contrast agents for noninvasive tumor imaging or by therapeutic compounds that have preferential effects on cancer cells. These strategies should also aim to exploit the specific intracellular targeting of the B-subunit via the retrograde pathway for tumor-specific activation and targeted delivery of compounds to selected intracellular sites, while at the same time avoiding degradation and inactivation in late endosomes/lysosomes. Such developments are currently under investigation in a number of laboratories around the world and are expected to yield promising results in the near future.
Conclusions
In this review, we have described how the initial immunotoxin concept may evolve to take advantage of nontoxic, receptor-binding, and trafficking subunits of protein toxins for the targeted delivery of tumor diagnostics and therapeutics. Focusing on Shiga toxin B-subunit as an example, it was shown that this protein exclusively binds to a cellular receptor, the glycolipid Gb3, with a markedly restricted expression pattern that allows designing compositions, which specifically target certain cells types, such as antigen-presenting cells (exploitation for immunotherapy) or tumor cells (exploitation for tumor targeting). In addition to cell specificity, the B-subunit also has intracellular trafficking characteristics that allow it to avoid recycling and degradation and to reach specific intracellular sites, such as the Golgi apparatus, the endoplasmic reticulum, and in some instances the cytosol. These targeting and trafficking characteristics are currently exploited for the development of new immunotherapy and cancer cell targeting approaches.
Apart from targeting and trafficking, Shiga toxin Bsubunit also has other characteristics that may be of importance in the development of the above-mentioned vectorization approaches, such as small size, resistance to the intestinal milieu (pH and proteases), crossing of the intestinal mucosa, and distribution in the body. These characteristics are the result of its evolution with mammalian hosts as a product of intestinal pathogens. In mice, the B-subunit has been described as a low immunogenic protein with major histocompatibility complex dependence. 107 The same seems to hold true in human. Indeed, in one study, among 30 patients with Shiga-like toxin (or verotoxin (VT); note that VT1, or Shiga-like toxin 1, is essentially the same protein as Shiga toxin) induced hemolytic and uremic syndrome, no one had antibodies to VT1 or VT2. 108 Ludwig et al 109 reported that 31% of patients with hemolytic and uremic syndrome had antibodies to Shiga-like toxin 2, while only 5% had antibodies to Shiga-like toxin 1. Similarly, among healthy patients, 10% had antibodies to Shiga-like toxin 2, and only 1.8% to Shiga-like toxin 1. In another study, 6/21 patients with Shigella dysenteriae induced diarrhea had antibodies to Shiga holotoxin, but no one to B-subunit derived peptides. 110 However, it cannot be excluded that in a therapeutic setting that uses Shiga toxin B-subunit as a vectorization tool, repetitive injection of the protein leads to a neutralizing antibody response. If that was the case, it may be achieved to maintain Gb3 targeting while changing the targeting vector, as various Shiga-like toxins with limited sequence identity have been described that all have Gb3 binding capacity. 111 Furthermore, a peptide was recently identified with significant affinity for Gb3. 112 Intracellular trafficking for targeted therapy L Johannes and D Decaudin
As described in this review, Shiga toxin B-subunit has naturally evolved to transport an exogenous protein, the catalytic A-subunit, from the outside of cells into the cytosol, and it can also be used for the delivery of antigenic proteins to the cytosol of dendritic cells. 88 In this context, it is noteworthy that Shiga toxin B-subunit binds to a nucleolar protein that shuttles between cytosol and nucleoplasm. 114 Whether these different activities can be exploited to increase the efficiency of nonviral vector delivery to specific cells remains to be explored.
In conclusion, receptor-binding protein toxin moieties hold out the promise of better therapeutics and diagnostics that exploit many of their remarkable characteristics, notably their trafficking to selected intracellular sites.
